Format

Send to

Choose Destination
Expert Rev Vaccines. 2019 Feb;18(2):105-117. doi: 10.1080/14760584.2019.1562909. Epub 2019 Jan 17.

Next generation designer virus-like particle vaccines for dengue.

Author information

1
a Recombinant Gene Products Group, Molecular Medicine Division , International Centre for Genetic Engineering & Biotechnology , New Delhi , India.
2
b NCR Biotech Science Cluster , Translational Health Science & Technology Institute , Faridabad , India.

Abstract

INTRODUCTION:

A safe and efficacious vaccine for dengue continues to be an unmet public health need. The recent licensing of a dengue vaccine (Dengvaxia) developed by Sanofi has brought to the fore the safety issue of vaccine-induced infection enhancement.

AREAS COVERED:

This article focuses on two new yeast-produced tetravalent dengue envelope domain III-displaying virus-like particulate vaccine candidates reported in early 2018 and reviews the rationale underlying their design, and pre-clinical data which suggest that these may offer promising alternate options.

EXPERT COMMENTARY:

These are the only vaccine candidates so far to have demonstrated the induction of primarily serotype-specific neutralizing antibodies to all dengue virus serotypes in experimental animals. Interestingly, these antibodies lack infection-enhancing potential when evaluated using the AG129 mouse model.

KEYWORDS:

; Dengue vaccine; envelope domain III; live attenuated vaccine; virus-like particle

PMID:
30587054
DOI:
10.1080/14760584.2019.1562909
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center